Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

Overview of attention for article published in BMC Cancer, March 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 7,651 followers.

Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain https://t.co/Ja7dsSiWrU https://t.co/kEnvSAaHl0

RT @BibliotecaHUCA: PubMed-https://t.co/CA0hSTlYxX Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing'…

RT @BibliotecaHUCA: PubMed-https://t.co/CA0hSTlYxX Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing'…

RT @BibliotecaHUCA: PubMed-https://t.co/CA0hSTlYxX Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing'…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.